Navigation Links
Aspirin intake may stop growth of vestibular schwannomas/acoustic neuromas
Date:1/23/2014

BOSTON (Jan. 24, 2014) Researchers from Massachusetts Eye and Ear, Harvard Medical School, Massachusetts Institute of Technology and Massachusetts General Hospital have demonstrated, for the first time, that aspirin intake correlates with halted growth of vestibular schwannomas (also known as acoustic neuromas), a sometimes lethal intracranial tumor that typically causes hearing loss and tinnitus.

Motivated by experiments in the Molecular Neurotology Laboratory at Mass. Eye and Ear involving human tumor specimens, the researchers performed a retrospective analysis of over 600 people diagnosed with vestibular schwannoma at Mass. Eye and Ear. Their research suggests the potential therapeutic role of aspirin in inhibiting tumor growth and motivates a clinical prospective study to assess efficacy of this well-tolerated anti-inflammatory medication in preventing growth of these intracranial tumors.

"Currently, there are no FDA-approved drug therapies to treat these tumors, which are the most common tumors of the cerebellopontine angle and the fourth most common intracranial tumors," explains Konstantina Stankovic, M.D., Ph.D., Mass. Eye and Ear clinican-researcher and assistant professor of otology andlaryngology, Harvard Medical School, who led the study. "Current options for management of growing vestibular schwannomas include surgery (via craniotomy) or radiation therapy, both of which are associated with potentially serious complications."

The findings, which are described in the February issue of the journal Otology and Neurotology, were based on a retrospective series of 689 people, 347 of whom were followed with multiple magnetic resonance imaging MRI scans (50.3%). The main outcome measures were patient use of aspirin and rate of vestibular schwannoma growth measured by changes in the largest tumor dimension as noted on serial MRIs. A significant inverse association was found among aspirin users and vestibular schwannoma growth (odds ratio: 0.50, 95 percent confidence interval: 0.29-0.85), which was not confounded by age or gender.

"Our results suggest a potential therapeutic role of aspirin in inhibiting vestibular schwannoma growth," said Dr. Stankovic, who is an otologic surgeon and researcher at Mass. Eye and Ear, Assistant Professor of Otology and Laryngology, Harvard Medical School (HMS), and member of the faculty of Harvard's Program in Speech and Hearing Bioscience and Technology.


'/>"/>

Contact: Mary Leach
Mary_Leach@meei.harvard.edu
617-573-4170
Massachusetts Eye and Ear Infirmary
Source:Eurekalert

Related biology news :

1. A new form of aspirin to overcome aspirin resistance
2. Research shows how aspirin may act on blood platelets to improve survival in colon cancer patients
3. Modest alcohol intake associated with less inflammation in patients with common liver disease
4. Red potato chips: Segmentation cues can substantially decrease food intake
5. Fast food restaurant lighting and music can reduce calorie intake and increase satisfaction
6. Omega-3 intake heightens working memory in healthy young adults
7. Research provides new insights into dogs natural feeding behavior and finds they target a daily dietary intake that is high in fat
8. New health-economic model shows benefits of boosting dietary calcium intake
9. Community-based nutrition education shown to be successful in increasing calcium intake
10. Cats are able to navigate complex combinations of wet and dry foods to achieve a consistent intake of protein, fat and carbohydrate
11. New study sheds light on link between dairy intake and bone health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
(Date:3/21/2016)... , March 22, 2016 ... with passcodes for superior security   ... leading provider of secure digital communications services, today announced ... technology and offer enterprise customers, particularly those in the ... recognition and voice authentication within a mobile app, alongside, ...
Breaking Biology News(10 mins):
(Date:5/27/2016)... and READING, England , ... Indegene ( http://www.indegene.com ), ein führender Anbieter ... die Life-Science-Branche, Pharmaunternehmen und Gesundheitsorganisationen, und TranScrip ... von innovativen wissenschaftlichen Support-Services für den gesamten ... IntraScience heute den Ausbau ihrer bestehenden Allianz ...
(Date:5/26/2016)... Despite the volatility that continues to ... Today,s pre-market research on ActiveWallSt.com directs the investor community,s focus ... RDUS ), Cerus Corp. (NASDAQ: CERS ), ... Prime Therapeutics Inc. (NASDAQ: FPRX ). Register with ... http://www.activewallst.com/ On Wednesday, shares in ...
(Date:5/25/2016)... ... May 25, 2016 , ... Thailand’s Board of Investment’s New ... San Francisco. Located at booth number 7301, representatives from the Thai Government, research ... the Thai biotechnology and life sciences sector. , Deputy Secretary General of ...
(Date:5/25/2016)... ... May 25, 2016 , ... WEDI, the nation’s leading authority on the ... Charles W. Stellar has been named by the WEDI Board of Directors as WEDI’s ... an executive leader with more than 35 years of experience in healthcare, association management ...
Breaking Biology Technology: